Literature DB >> 19567910

Recurrence up to 3.5 years after antibiotic treatment of acute otitis media in very young Dutch children: survey of trial participants.

Natália Bezáková1, Roger A M J Damoiseaux, Arno W Hoes, Anne G M Schilder, Maroeska M Rovers.   

Abstract

OBJECTIVE: To determine the long term effects of antibiotic treatment for acute otitis media in young children.
DESIGN: Prospective three year follow-up study within the framework of a primary care based, double blind, randomised, placebo controlled trial.
SETTING: 53 general practices in the Netherlands. PARTICIPANTS: 168 children aged 6 months to 2 years with acute otitis media.
INTERVENTIONS: Amoxicillin 40 mg/kg/day in three doses compared with placebo. MAIN OUTCOME MEASURES: Recurrence of acute otitis media; referral to secondary care; ear, nose, and throat surgery.
RESULTS: Acute otitis media recurred in 63% (47/75) of children in the amoxicillin group and in 43% (37/86) of the placebo group (risk difference 20%, 95% confidence interval 5% to 35%); 30% (24/78 amoxicillin; 27/89 placebo) of children in both groups were referred to secondary care, and 21% (16/78) of the amoxicillin group compared with 30% (27/90) of the placebo group had ear, nose, and throat surgery (risk difference -9%, -23% to 4%).
CONCLUSION: Recurrent acute otitis media occurred more often in the children originally treated with amoxicillin. This is another argument for judicious use of antibiotics in children with acute otitis media. Trial registration Netherlands Trial Register NTR1426.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19567910      PMCID: PMC3272660          DOI: 10.1136/bmj.b2525

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


Introduction

Acute otitis media, one of the most common infections in childhood, remains the leading cause of doctors’ consultations by children and the most common reason for children to take antibiotics.1 Current guidelines recommend prescription of antibiotics in children with severe illness and in those younger than 2 years of age with bilateral acute otitis media or acute otorrhoea. For most other children with acute otitis media, initial observation is recommended.2 3 4 So far, little is known about the long term effects of antibiotics in acute otitis media. Initial prescription of antibiotics may on the one hand shorten the course of acute otitis media.5 6 On the other hand, it may encourage doctors’ attendance in future episodes, increase pressure on doctors to prescribe, increase future use of antibiotics, and therefore increase antibiotic resistance.7 8 In addition, antibiotic treatment may cause an unfavourable shift towards colonisation with resistant pathogens, which are likely to promote recurrence of the infection.9 10 11 12 We aimed to study the long term effects of antibiotics on recurrence of acute otitis media; referrals to secondary care; and ear, nose, and throat surgery.

Methods

We did the study within the framework of a primary care based, randomised, placebo controlled, double blind trial on the effects of amoxicillin compared with placebo in children with acute otitis media aged between 6 and 24 months.5 The diagnosis of acute otitis media was based on the presence of acute signs of infection and otoscopy. The original study took place in the Netherlands between February 1996 and May 1998 and included 240 children, who were followed actively for six months.5 13 At trial entry, parents were informed that treatment allocation would be revealed only after the final follow-up, including the post-trial period of about three years. Only in case of severe complications or side effects would the treatment code be broken during the trial. The results at days four and 11 and at six months were reported in 2000 and 2006.5 13 In 2000—that is, approximately three and half years after the start of the trial—we sent a questionnaire to parents of the participating children, asking them about episodes of recurrent acute otitis media; referral to secondary care; and ear, nose, and throat surgery. We defined the primary outcome measure, reported recurrent acute otitis media, as at least one episode of acute otitis media that occurred between the last study appointment at six months and the current survey. In addition, we compared the proportion of children referred to secondary care (paediatrician or ear, nose, and throat surgeon) and the rate of ear, nose, and throat surgery. In the first instance, we looked only at risk difference and did not adjust for potential confounders, as we were reporting on the long term effects of a randomised placebo controlled trial. To be sure that confounding was not a problem in the post-randomisation period, we also studied the following potential confounders by using logistic regression analysis: mean age at inclusion, sex, breast feeding, number of siblings, season of inclusion, attendance at day care centre, family history of recurrent upper respiratory tract infections, (duration of) symptoms at presentation, subsequent use of antibiotics within six months, and the clinical outcome at days four and 11 and six months. Finally, we did a sensitivity analysis on the primary outcome restricted to the children in each group who did not receive antibiotics within the first six months of the post-trial follow-up period. We did all analyses with SPSS 14.0 on an intention to treat basis.

Results

Of the 240 participants originally randomised, 168 (70%) returned the questionnaire. At this stage, about 95% of these parents were still blinded to the original treatment. The baseline characteristics of these 168 children were similar to those initially randomised (table 1).
Table 1

 Baseline characteristics. Values are numbers (percentages) unless stated otherwise

CharacteristicTrial (n=240)Long term survey (n=168)
Amoxicillin (n=117)Placebo (n=123)Amoxicillin (n=78)Placebo (n=90)
Mean age at inclusion (months)13.313.413.513.1
Male64 (55)66 (54)43 (55)45 (50)
Breast fed for ≥6 months21 (18)22 (18)17 (22)17 (19)
>2 children in family30 (26)25 (20)19 (24)18 (20)
Season of inclusion (Oct-March)76 (65)79 (64)52 (67)60 (67)
Smoking in household46 (39)39 (32)27 (35)24 (27)
Attendance at day care centre28 (24)19 (15)19 (24)16 (18)
Medical history:
 Recurrent URTI37 (32)33 (27)24 (31)19 (21)
 Recurrent AOM in family26 (22)33 (27)15 (19)25 (28)
 Allergy14 (12)9 (7)7 (9)7 (8)
 Recurrent AOM33 (28)50 (41)21 (27)33 (37)
Clinical presentation:
 >3 days’ complaints57 (49)54 (44)39 (50)39 (43)
 Earache82 (70)82 (67)57 (73)58 (64)
 Fever79 (68)80 (65)51 (65)54 (60)
 Perforation18 (15)21 (17)13 (17)19 (21)
 Bilateral AOM75 (64)76 (62)51 (65)55 (61)
 Bulging ear drum26 (22)29 (24)21 (27)18 (20)
Mean follow-up (months)NANA4645
Subsequent antibiotic use within 6 months*39/105 (37)44/104 (42)23/73 (32)32/81 (40)

AOM=acute otitis media; NA=not applicable; URTI=upper respiratory tract infection.

*At least one antimicrobial treatment within six months of end of treatment.

Baseline characteristics. Values are numbers (percentages) unless stated otherwise AOM=acute otitis media; NA=not applicable; URTI=upper respiratory tract infection. *At least one antimicrobial treatment within six months of end of treatment. Three years after randomisation, acute otitis media had recurred in 47/75 (63%) children in the amoxicillin group compared with 37/86 (43%) children in the placebo group (risk difference 20%, 95% confidence interval 5% to 35%) (table 2). Logistic regression analysis showed that sex, allergy, and history of recurrent acute otitis media might be relevant confounding factors. Adjustment for these factors resulted in an adjusted odds ratio of 2.5 (95% confidence interval 1.2 to 5.0)—that is, children who were assigned to the amoxicillin group had a 2.5 times higher risk of recurrent acute otitis media than children in the placebo group.
Table 2

 Clinical outcomes between six months and three years after randomised controlled trial. Values are numbers (percentages) unless stated otherwise

OutcomeAmoxicillin (n=78)Placebo (n=90)Risk difference (95% CI)Relative risk (95% CI)
Recurrent acute otitis media47/75 (63)37/86 (43)20% (5% to 35%)1.5 (1.1 to 2.0)
Referral rate24 (31)27/89 (30)0% (−14% to 14%)1.0 (0.6 to 1.6)
Surgery rate16 (21)27 (30)−9% (−23% to 4%)0.7 (0.4 to 1.2)
Clinical outcomes between six months and three years after randomised controlled trial. Values are numbers (percentages) unless stated otherwise Twenty four out of 78 (31%) children in the amoxicillin group and 27/89 (30%) in the placebo were referred to secondary care (risk difference 0%, −14% to 14%) (table 2). Finally, 16/78 (21%) children in the amoxicillin group compared with 27/90 (30%) children in the placebo group had ear, nose, and throat surgery (risk difference −9%, −23% to 4%). Sensitivity analysis for the primary outcome measure, comparing only those children in each group who did not receive antibiotics in the first six months of the post-trial follow-up period, showed a risk difference of 32% (13% to 51%) and an adjusted odds ratio of 4.4 (1.7 to 11.5).

Discussion

Using a questionnaire about recurrent episodes of acute otitis media, we found a 20% higher recurrence rate in the amoxicillin group compared with the placebo group in the post-trial period between six months and three years after randomisation. The corresponding confidence intervals, however, are wide, so this rate must be interpreted with some caution. To our knowledge, we are the first group to study the long term effects of antibiotics in children with acute otitis media. Others have studied the effects up to one year and found no differences between the groups.8 14 This seems to be in agreement with our results for the first six months of follow-up, in which we found similar recurrence rates in the amoxicillin and placebo group (51% v 50%; risk difference 1%, 95% confidence interval −12% to 15%). Our findings might be explained by unfavourable changes in the colonisation of the nasopharynx as a result of the use of antibiotics, as reported previously.9 10 11 12 Alternatively, the use of antibiotics early in an episode of acute otitis media may impair the natural immune response and weaken the protection against further episodes, as has been suggested in studies of bacterial pharyngitis.15 16 17 Importantly, both possible explanations would primarily have resulted in a difference in recurrence of acute otitis media in the first six months of follow-up, which was not the case. Nevertheless, our findings are very robust: unadjusted, adjusted, and sensitivity analyses showed a relevant clinical difference. The major strength of our study is the fact that most parents were still blinded to the original treatment when they filled in the questionnaire. Furthermore, by using a questionnaire we measured true recurrences rather than reattendances. Some possible limitations deserve further discussion. Firstly, under-reporting or over-reporting of acute otitis media cannot fully be precluded, as the outcomes were based on parental reports. The recurrence rates might therefore be biased, but we would expect a similar effect in both groups, especially as most parents were still blinded when they participated in the current survey. Thus recall bias is unlikely. Secondly, 70% of the parents who participated in the randomised controlled trial returned the questionnaire. This might potentially have led to selection of otitis prone children. The baseline characteristics of the children whose parents responded were, however, similar to those of the original trial population. Thirdly, we did not do a Cox regression analysis, as we measured only the number of recurrent episodes after three years. As the mean follow-up times were similar in both groups, however, we do not expect that Cox regression would have changed our results. Fourthly, our results can be generalised only to otherwise healthy children in well resourced settings. Acute otitis media can become a serious illness in children at risk and in those in less resourced settings, and this may call for a more active approach to treatment. Fifthly, owing to the delay in reporting the results of this survey, changes in practice since then may have reduced the applicability of our results. As antibiotics are still widely prescribed in young children with acute otitis media,18 however, we believe that the results of our study are still applicable to current day to day practice. In conclusion, recurrent acute otitis media occurred more often in the children originally treated with amoxicillin. This is another argument for judicious use of antibiotics in children with acute otitis media. Antibiotics shorten the course of acute otitis media but encourage doctors’ attendance in future episodes and antibiotic resistance Evidence on the long term effects of antibiotics in children with acute otitis media is lacking Recurrent acute otitis media occurred more often in the children originally treated with amoxicillin This is another argument for judicious use of antibiotics in children with acute otitis media
  17 in total

1.  Primary care based randomised, double blind trial of amoxicillin versus placebo for acute otitis media in children aged under 2 years.

Authors:  R A Damoiseaux; F A van Balen; A W Hoes; T J Verheij; R A de Melker
Journal:  BMJ       Date:  2000-02-05

2.  Penicillin for acute sore throat: randomised double blind trial of seven days versus three days treatment or placebo in adults.

Authors:  S Zwart; A P Sachs; G J Ruijs; J W Gubbels; A W Hoes; R A de Melker
Journal:  BMJ       Date:  2000-01-15

3.  Antibiotic treatment in acute Otitis Media promotes superinfection with resistant Streptococcus pneumoniae carried before initiation of treatment.

Authors:  R Dagan; E Leibovitz; G Cheletz; A Leiberman; N Porat
Journal:  J Infect Dis       Date:  2001-02-09       Impact factor: 5.226

4.  A single intramuscular dose of ceftriaxone changes nasopharyngeal bacterial flora in children with acute otitis media.

Authors:  T Heikkinen; K A Saeed; D P McCormick; C Baldwin; B S Reisner; T Chonmaitree
Journal:  Acta Paediatr       Date:  2000-11       Impact factor: 2.299

5.  Effects of large dosages of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, nonpneumococcal alpha-hemolytic streptococci, and Staphylococcus aureus in children with acute otitis media.

Authors:  Faryal Ghaffar; Luz Stella Muniz; Kathy Katz; Jeanette L Smith; Theresa Shouse; Phyllis Davis; George H McCracken
Journal:  Clin Infect Dis       Date:  2002-04-24       Impact factor: 9.079

Review 6.  Antibiotics for acute otitis media in children.

Authors:  P P Glasziou; C B Del Mar; S L Sanders; M Hayem
Journal:  Cochrane Database Syst Rev       Date:  2004

7.  Has UK guidance affected general practitioner antibiotic prescribing for otitis media in children?

Authors:  P L Thompson; R E Gilbert; P F Long; S Saxena; M Sharland; I C K Wong
Journal:  J Public Health (Oxf)       Date:  2008-09-01       Impact factor: 2.341

8.  Acute red ear in children: controlled trial of non-antibiotic treatment in general practice.

Authors:  P Burke; J Bain; D Robinson; J Dunleavey
Journal:  BMJ       Date:  1991-09-07

Review 9.  Diagnosis and management of acute otitis media.

Authors: 
Journal:  Pediatrics       Date:  2004-05       Impact factor: 7.124

Review 10.  Otitis media.

Authors:  Maroeska M Rovers; Anne G M Schilder; Gerhard A Zielhuis; Richard M Rosenfeld
Journal:  Lancet       Date:  2004-02-07       Impact factor: 79.321

View more
  10 in total

1.  The evidence for applying Streptococcus salivarius 24SMB by nasal spray for preventing recurrent acute otitis media.

Authors:  P Marchisio; S Esposito; N Principi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-26       Impact factor: 3.267

2.  Streptococcus salivarius by nasal spray for recurrent otitis: how good is the evidence?

Authors:  S Di Mario; V Basevi; R D'Amico; C Gagliotti; M Gangemi; F Marchetti; M L Moro; G Tamburlini
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-14       Impact factor: 3.267

Review 3.  Acute infective conjunctivitis in primary care: who needs antibiotics? An individual patient data meta-analysis.

Authors:  Joanna Jefferis; Rafael Perera; Hazel Everitt; Henk van Weert; Remco Rietveld; Paul Glasziou; Peter Rose
Journal:  Br J Gen Pract       Date:  2011-09       Impact factor: 5.386

Review 4.  Antibiotics for acute otitis media in children.

Authors:  Roderick P Venekamp; Sharon L Sanders; Paul P Glasziou; Chris B Del Mar; Maroeska M Rovers
Journal:  Cochrane Database Syst Rev       Date:  2015-06-23

5.  "One-size-fits-all"? Optimizing treatment duration for bacterial infections.

Authors:  Patricia Geli; Ramanan Laxminarayan; Michael Dunne; David L Smith
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

6.  Parents' beliefs and knowledge about the management of acute otitis media: a qualitative study.

Authors:  Malene Plejdrup Hansen; Janine Howlett; Chris Del Mar; Tammy C Hoffmann
Journal:  BMC Fam Pract       Date:  2015-07-07       Impact factor: 2.497

7.  Antibiotic Use in Children with Acute Respiratory or Ear Infections: Prospective Observational Comparison of Anthroposophic and Conventional Treatment under Routine Primary Care Conditions.

Authors:  Harald J Hamre; Anja Glockmann; Reinhard Schwarz; David S Riley; Erik W Baars; Helmut Kiene; Gunver S Kienle
Journal:  Evid Based Complement Alternat Med       Date:  2014-11-18       Impact factor: 2.629

8.  Antibiotic Treatment for First Episode of Acute Otitis Media Is Not Associated with Future Recurrences.

Authors:  Marthe Te Molder; Marieke L A de Hoog; Cuno S P M Uiterwaal; Cornelis K van der Ent; Henriette A Smit; Anne G M Schilder; Roger A M J Damoiseaux; Roderick P Venekamp
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

Review 9.  Natural history, definitions, risk factors and burden of otitis media.

Authors:  Kelvin Kong; Harvey L C Coates
Journal:  Med J Aust       Date:  2009-11-02       Impact factor: 7.738

10.  Beta- lactam antibiotics stimulate biofilm formation in non-typeable haemophilus influenzae by up-regulating carbohydrate metabolism.

Authors:  Siva Wu; Xiaojin Li; Manjula Gunawardana; Kathleen Maguire; Debbie Guerrero-Given; Christoph Schaudinn; Charles Wang; Marc M Baum; Paul Webster
Journal:  PLoS One       Date:  2014-07-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.